Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, Filip K. Knop, Ildiko Lingvay, Stanislava Macura, Chantal Mathieu, Sue D. Pedersen, Melanie J. Davies
Topics & Concepts
SemaglutideMedicineType 2 diabetesClinical endpointInternal medicineRandomized controlled trialAdverse effectIntention-to-treat analysisExenatideDiabetes mellitusDulaglutidePhysical therapyLiraglutideEndocrinologyDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins